Stephens Inc’s Sarepta Therapeutics SRPT Stock Holding History

Stephens Inc’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,712	Closed	-$351K	–	1346
2024 Q1	$351K	Buy	+2,712	New	+$332K	0.01%	945
2023 Q2	–	Sell	-1,562	Closed	-$215K	–	1282
2023 Q1	$215K	Hold	1,562	–	–	﹤0.01%	1003
2022 Q4	$202K	Buy	+1,562	New	+$181K	﹤0.01%	1008
2020 Q4	–	Sell	-1,500	Closed	-$211K	–	1265
2020 Q3	$211K	Hold	1,500	–	–	﹤0.01%	1009
2020 Q2	$241K	Buy	+1,500	New	+$204K	0.01%	908
2019 Q3	–	Sell	-1,500	Closed	-$228K	–	1200
2019 Q2	$228K	Buy	+1,500	New	+$182K	0.01%	1023
2018 Q4	–	Sell	-1,500	Closed	-$242K	–	1179
2018 Q3	$242K	Buy	+1,500	New	+$205K	0.01%	989

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Stephens Inc's SRPT Position: Q2 2024 in Review

Stephens Inc sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 2,712 shares — an estimated $351K sold.

Stephens Inc first reported a position in SRPT in Q3 2018 and held it in 7 quarters. The position peaked at $351K in Q1 2024. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

Stephens Inc reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
Stephens Inc sold 2,712 Sarepta Therapeutics shares in Q2 2024, an estimated $351K.
Stephens Inc first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 7 quarters.
Stephens Inc's Sarepta Therapeutics position peaked at $351K in Q1 2024.
483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Stephens Inc's 13F filing for Q2 2024, filed 6 Aug 2024.